Lantheus (LNTH) to Release Earnings on Wednesday

Lantheus (NASDAQ:LNTH - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect Lantheus to post earnings of $1.64 per share and revenue of $377.37 million for the quarter.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded up $1.03 during midday trading on Tuesday, reaching $103.73. 78,112 shares of the company's stock were exchanged, compared to its average volume of 951,277. The firm's 50 day simple moving average is $97.80 and its two-hundred day simple moving average is $95.08. Lantheus has a fifty-two week low of $65.76 and a fifty-two week high of $126.89. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of 17.20 and a beta of 0.20.

Insider Buying and Selling at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LNTH. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. JMP Securities reissued a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.